

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

NISHIMURA, et al.

Serial No: Not Assigned; Parent 09/439,779

Filed: July 15, 2003

For: A Peptide and Osteogenetic  
Accelerator

Art Unit: Not Assigned

Examiner: Not Assigned

**TRANSMITTAL OF INFORMATION  
DISCLOSURE STATEMENT**

Mail Stop: PATENT APPLICATION

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sirs:

1. ☒ The information disclosure statement submitted herewith is being filed within three months of the filing date of the application other than a continued prosecution application, or within three months of the date of entry into the national stage of an international application, or before the mailing date of a first Office Action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under §1.114, whichever event occurs last. 37 C.F.R. §1.97(b).
2. ☐ The information disclosure statement transmitted herewith is being filed *after* the period specified in §1.97(b), but *before* the mailing date of a final action under §1.113, or a notice of allowance under §1.311, or an action that otherwise closes prosecution in the application, whichever occurs first. A statement specified in §1.97(e) or a fee set forth in §1.17(p) is included. 37 C.F.R. §1.97(c).

**§1.97(e) STATEMENT**

I, the person signing below, state:

- ☐ that each item of information contained in the information disclosure statement was first cited in the attached communication from a foreign patent office in a counterpart foreign application and that the communication is dated not more than three months prior to the filing of the statement. 37 C.F.R. §1.97(e)(1).

OR

- ☐ that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification

Express Mail Label No. EV 325 216 006 US

after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the statement. 37 C.F.R. §1.97(e)(2).

**OR FEE**

- ☐ Attached is a fee set forth in 37 C.F.R. §1.17(p) for submission of an information disclosure statement under §1.97(c). (\$180.00). [OR:] Please charge the fee set forth in 37 C.F.R. §1.17(p) for submission of an information disclosure statement under §1.97(c) (\$180.00) to Deposit Account No. 50-1314. A copy of this petition is enclosed.

3. ☐ The information disclosure statement transmitted herewith is being filed *after* the period specified in §1.97(c), but before, or simultaneously with the payment of the issue fee. A statement specified in §1.97(e) and a fee set forth in §1.17(p) are included. 37 C.F.R. §1.97(d).

**§1.97(e) STATEMENT**

I, the person signing below, state:

- ☐ that each item of information contained in the information disclosure statement was first cited in the attached communication from a foreign patent office in a counterpart foreign application and that the communication is dated not more than three months prior to the filing of the statement. 37 C.F.R. §1.97(e)(1).

**OR**

- ☐ that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the statement. 37 C.F.R. §1.97(e)(2).

**AND FEE**

- ☐ Attached is a fee set forth in 37 C.F.R. §1.17(p) for submission of an information disclosure statement under §1.97(d). (\$180.00).
4. ☒ If it should be determined that for any reason either an insufficient fee or an excessive has been paid, please charge any insufficiency or credit any overpayment necessary to ensure consideration of the information disclosure statement for the above-identified application to Deposit Account No. 50-1314. **A copy of this petition is enclosed.**

5. ☒ A list of 15 reference(s) is in the enclosed Form PTO-1449. Pursuant to 37 C.F.R. § 1.98(d), copies of the listed reference(s) are not provided since they were submitted in parent application Serial No. 09/439,779, the benefit of the filing date of which is claimed herein under 35 U.S.C. § 120.

**NON-ENGLISH LANGUAGE REFERENCES**


- ☐ Enclosed is a search report for a counterpart application. The search report Examiner has provided comments on the relevancy of any non-English language references cited in the search report.
- ☐ The specification incorporates comments on the relevancy of Non-English language references.
- ☐ Set forth below are comments provided by the applicant's home country counsel on the relevancy of non-English language references:

Date: July 15, 2003

Biltmore Tower  
500 South Grand Avenue, Suite 1900  
Los Angeles, CA 90071  
Telephone: (213) 337-6700  
Facsimile: (213) 337-6701

Respectfully submitted,  
HOGAN & HARTSON L.L.P.

By:

  
Lawrence J. McClure  
Registration No. 44,228  
Attorney for Applicant(s)

<b>FORM PTO-1449</b>			<b>Docket Number (Optional)</b> 81918.0003		<b>Application Number</b> Not Assigned; Parent 09/439,779	
<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>			<b>Applicant</b> <div style="text-align: right;">NISHIMURA, et al.</div>			
<i>(Use several sheets if necessary)</i>			<b>Filing Date</b> July 15, 2003		<b>Group Art Unit</b> Not Assigned	
<b>U.S. PATENT DOCUMENTS</b>						
<b>EXAMINER INITIAL</b>	<b>DOCUMENT NUMBER</b>	<b>DATE</b>	<b>NAME</b>	<b>CLASS</b>	<b>SUBCLASS</b>	<b>FILING DATE IF APPROPRIATE</b>
<b>FOREIGN PATENT DOCUMENTS</b>						
	<b>DOCUMENT NUMBER</b>	<b>DATE</b>	<b>COUNTRY</b>	<b>CLASS</b>	<b>SUBCLASS</b>	<b>TRANSLATION (YES/NO)</b>
	EP 99402815	09/11/00	EPO			
	6/298,800	10/25/94	Japan			
	10/070,989	03/17/98	Japan			
	06/296,677	10/25/94	Japan			
	07/246,235	09/26/95	Japan			
	07/116,240	09/05/95	Japan			
	07/088,174	04/04/95	Japan			
	10/151,188	06/09/98	Japan			
	WO 89/09787	10/19/89	WO			
	WO 89/09788	10/1989	WO			
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>						
	Database Biosis 'Online! Biosciences Information Service Philadelphia, PA, US: R. Bellamkonda, et al.: "Laminin oligopeptide derivatized agarose gels allow three-dimensional neurite extension in vitro" XP002145150 & J. Neuroscience Research, 1995, Vol. 41, pgs. 501-509					
	T.J. Gao, et al.: "Bone inductive potential and dose-dependent response of bovine bone morphogenetic protein combined with type IV collagen carrier" Annales Chirurgiae et Gynaecologiae, vol. 82, 1993, pages 77-84					
	S. Ijiri, et al., : "Ectopic bone induction in porous apatite-wollastonite-containing glass ceramic combined with bone morphogenetic protein" J. Biomed. Mater. Res., vol. 35, no. 4, 15 June 1997 (1997-06-15) pages 421-432					
	Novel Regulators of Bone Formation: Molecular Clones and Activities; Wozney, et al. / Science, Vol. 242: Research Articles, pgs. 1528-1534 / 12/16/88					
	"Recombinant human bone morphogenetic protein induces bone formation"; Wang, et al.; Proc. Natl. Acad.: Sci. USA, vol. 87, pp. 2220-2224, March 1990, Biochemistry					
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.						